Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 358

1.

Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ.

J Natl Cancer Inst. 2011 Jun 22;103(12):962-78. doi: 10.1093/jnci/djr156. Epub 2011 Jun 8.

2.

BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.

Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J.

Oncotarget. 2016 Jul 12;7(28):43504-43517. doi: 10.18632/oncotarget.9762.

3.

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.

Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ.

Clin Cancer Res. 2016 Aug 15;22(16):4105-18. doi: 10.1158/1078-0432.CCR-15-2624. Epub 2016 Mar 15.

4.

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.

Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ.

Neoplasia. 2011 Feb;13(2):145-53.

5.

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.

Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.

Oncotarget. 2016 Jan 12;7(2):1451-63. doi: 10.18632/oncotarget.6385.

6.

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.

Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ.

Clin Cancer Res. 2014 Mar 1;20(5):1190-203. doi: 10.1158/1078-0432.CCR-13-0901. Epub 2013 Nov 25.

7.

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.

Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.

8.

MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.

Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O.

Oncogene. 2013 Aug 15;32(33):3915-21.

PMID:
22986530
9.

High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.

He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.

Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.

PMID:
27760381
10.

A molecular function map of Ewing's sarcoma.

Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, Kovar H.

PLoS One. 2009;4(4):e5415. doi: 10.1371/journal.pone.0005415. Epub 2009 Apr 30.

11.

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.

Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.

Oncogene. 2014 Jul 24;33(30):3927-38. doi: 10.1038/onc.2013.361. Epub 2013 Sep 2.

12.

EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.

Ban J, Siligan C, Kreppel M, Aryee D, Kovar H.

Adv Exp Med Biol. 2006;587:41-52. Review.

PMID:
17163154
13.

Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.

Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Barber-Rotenberg JS, Houghton P, Üren A, Toretsky JA.

Oncotarget. 2014 Jan 30;5(2):338-50.

14.

The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.

Mendiola M, Carrillo J, García E, Lalli E, Hernández T, de Alava E, Tirode F, Delattre O, García-Miguel P, López-Barea F, Pestaña A, Alonso J.

Int J Cancer. 2006 Mar 15;118(6):1381-9.

15.

Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.

Jacques C, Lamoureux F, Baud'huin M, Rodriguez Calleja L, Quillard T, Amiaud J, Tirode F, Rédini F, Bradner JE, Heymann D, Ory B.

Oncotarget. 2016 Apr 26;7(17):24125-40. doi: 10.18632/oncotarget.8214.

16.

The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.

Vural C, Uluoğlu O, Akyürek N, Oğuz A, Karadeniz C.

Pathol Oncol Res. 2011 Sep;17(3):619-25. doi: 10.1007/s12253-010-9358-3. Epub 2011 Jan 26.

PMID:
21267687
17.

Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.

Uren A, Toretsky JA.

Future Oncol. 2005 Aug;1(4):521-8. Review.

PMID:
16556028
18.

Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.

Boro A, Prêtre K, Rechfeld F, Thalhammer V, Oesch S, Wachtel M, Schäfer BW, Niggli FK.

Int J Cancer. 2012 Nov 1;131(9):2153-64. doi: 10.1002/ijc.27472. Epub 2012 Mar 29.

19.

Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Aryee DN, Niedan S, Kauer M, Schwentner R, Bennani-Baiti IM, Ban J, Muehlbacher K, Kreppel M, Walker RL, Meltzer P, Poremba C, Kofler R, Kovar H.

Cancer Res. 2010 May 15;70(10):4015-23. doi: 10.1158/0008-5472.CAN-09-4333. Epub 2010 May 4.

20.

The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.

Sengupta A, Rahman M, Mateo-Lozano S, Tirado OM, Notario V.

Int J Oncol. 2013 Sep;43(3):803-12. doi: 10.3892/ijo.2013.2016. Epub 2013 Jul 12.

Supplemental Content

Support Center